Response of human ovarian carcinoma cell lines to antiprogestin mifepristone

Oncogene

Volumn 12, Issue 5, 1996, Pages 999-1003

  Rose, Faina V ^a   Barnea, Eytan R ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antiprogestin; Cell cycle; Mifepristone; Ovarian cancer; Progesterone receptor

Indexed keywords

ANTIGESTAGEN; MIFEPRISTONE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DNA CONTENT; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL DIVISION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029991071     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ahlgren J, Ellison N, Gottlieb R, Laluna F, Lokich J, Sinclair P, Ueno W, Wampler G, Yeung K, Alt D and Fryer J. (1993). J. Clin. Oncol., 11, 1957-1968.
2. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA and Klijn JG. (1990). J. Steroid Biochem. Mol. Biol., 37, 789-794.
3. Bertagna X, Escourolle H, Pinquier J, Coste J, Raux-Demay M, Perles P, Silvestre L, Luton J and Strauch G. (1994). J. Clin. Endocrinol. Metab., 78, 375-380.
4. Brenner R and Slayden O. (1994). Human Reproduc., 9, 82-97.
5. Dreicer R and Wilding G. (1992). Cancer Investig., 10, 27-41.
6. Galtier-Dereure F, Capony F, Maudelonde T and Rochefort H. (1992). J. Clin. Endocrin Metab., 75, 1497-1502.
7. Geisinger K, Berens M, Duckett Y, Morgan T, Kute T and Welander C. (1990). Cancer, 65, 1055-1061.
8. Graham II M, Bunn JR P, Jewett TP, Gonzalez-Aller C and Horowitz K. (1989). Cancer Research, 49, 3934-3942.
9. Ghosh D, De P and Sengupta J. (1992). Human Reproduc., 7, 1048-1060.
10. Horwitz KB. (1992). Endocr. Rev., 13, 146-163.
11. Kallioniemi OP, Punnonen R, Mattila J, Lentinen M and Keivula T. (1988). Cancer, 61, 334-339.
12. Kauppila A. (1984). Acta. Obstet. Gynecol. Scand., 63, 441-450.
13. Klemi P, Joensuu H, Maenpaa J and Kilholma P. (1989). Obstet. Gynecol., 74, 200-204.
14. Krigman H, Bentley R and Robboy S. (1994). Clin. Obstet. Gynecol., 37, 475-491.
15. Lebeau M and Baulieu E. (1994). Hum. Reprod., 9, 437-444.
16. Maentausta O, Svalander P, Danielson K, Bygdeman M and Vihko R. (1993). J. Clin. Endocrinol. Metab., 77, 913-918.
17. Milas L, Stephens L and Meyn R. (1994). In Vivo, 8, 665-673.
18. Mosmann T. (1983). J. Immunol. Methods. 65, 55-63.
19. Nicoletti M, Luvini V, Masazza G, Abbott B, D'Incalci M and Giavazzi R. (1993). Annals of Oncol., 4, 151-155.
20. Nordeen S, Bona B and Moyer M. (1993). Mol. Endocrinol., 7, 731-742.
21. Ozols RF. (1991). Cancer Treatment Rev., 18, 77.
22. Rao B and Slotman B. (1991). Endocr. Rev., 12, 14-26.
23. Reddel R and Sutherland K. (1987). Cancer Res., 47, 5323-5329.
24. Rotello R, Lieberman R, Lepoff R and Gerschenson L. (1992). Amer. J. Pathol., 140, 449-456.
25. Satyaswaroop P, Podczaski E and Mortel R. (1992). Principles and Practice of Gynecologic Oncology. WJ Hoskins, CA Perez and RC Young (eds.), pp. 151-166.
26. Sausville E. (1992). Principles and Practice of Gynecologic Oncology. WJ Hoskins, CA Perez and RC Young (eds.), Basic Science of Gynecologic Oncology, pp. 47-69.
27. Slotman B, Nauta J and Rao B. (1990). Cancer, 66, 740-744.
28. Thompson MA and Adelson MD. (1993). Adv. Exp. Med. Biol., 330, 155-165.
29. Woods L, Morgan R, Quina L, Moore G, Semple T and Stedman K. (1979). Cancer Res., 39, 4449-4459.